A/Prof Tim Clay
@drtclay
Followers
2K
Following
10K
Media
925
Statuses
6K
Medical oncologist from Perth - Australia. Interested in thoracic oncology, breast cancer, GUs, clinical trials, fast cars (Formula 1) and @werderbremen_en
Perth, Western Australia
Joined March 2013
Disappointing to see this from you, Georgie. You're fanning uninformed vitriol. When a population with appalling health measures at every level is rightly assessed as high risk & treated accordingly - to nobody else's detriment - it should be supported.
Race row erupts after Melbourne hospital gives Indigenous patients priority. The triaging of patients should be done on medical need, not the colour of your skin or race. A first glimpse of Jacinta Allan’s Treaty that will only divide Victorians.#springst
505
199
1K
🧬 Ever wondered what “VAF = 42%” means in your NGS report? Let’s decode it in simple terms 👇 When we sequence DNA, we get thousands of short fragments called reads. Some reads are 🧩 normal, others carry a 🧬 mutation. 👉 Variant Allele Frequency (VAF) tells us what fraction
0
62
272
It's almost here! Are you ready for TOGA's Post WCLC Symposium 2025? Don’t miss expert insights into the latest lung cancer trials and updates. 📅 Date: September 23 ⏰ Time: 6:30 - 8:00pm AEST 📍 Location: Online Can’t make it on the night? Catch up on demand.
1
1
1
One of the biggest influences on my career is Dr. Ross Camidge - a mentor and friend, an intellectual giant in the field of lung cancer who was diagnosed with this unforgiving disease himself. We are all at risk - and must all work to move the field. https://t.co/GHuaFBUoBm
news.cuanschutz.edu
D. Ross Camidge, MD, PhD, has spent his career fighting lung cancer. In 2022, that fight turned personal when he received a diagnosis of his own.
10
60
254
$NUVL #WCLC25
Dr. @alexdrilon at #WCLC25 presents important update on zidesamtinib in #ROS1 NSCLC. In previously treated subgroup, RR around 50% with very impressive duration of response, emerging around 2y.
6
2
5
🔥Recently presented at #WCLC25
#FLAURA2 trial- #Osimertinib + Chemo vs #Osimertinib in 1st line for patients with #EGFR+ advanced #NSCLC 🎯Median OS: 47.5 mo vs 37.6 👉Longest OS ever in a global phase 3 EGFRm NSCLC trial ✅No new safety signals ✅SOC #MedTwitter #OncTwitter
0
3
18
#WCLC25 In early-stage resectable NSCLC, serial ctDNA (Signatera) predicted recurrence with HR 88 (p<0.0001). Sensitivity 89% overall and 100% in stage IA. Supporting its role as a prognostic biomarker.
0
1
7
Ifinatamab deruxtecan (I-DXd) has received #FDA Breakthrough Therapy Designation in SCLC. Learn more about how this B7-H3–targeted medicine is showing promising results:
targetedonc.com
FDA designates ifinatamab deruxtecan as a breakthrough therapy for extensive-stage small cell lung cancer, promising improved treatment options for patients.
1
3
6
@exosome To be honest academic journals are rent-seeking middlemen. They don't fund the research, don't pay the authors, don't pay peer reviewers yet charge $3K–$10K per article or lock it behind $30 paywalls. They're economic highwaymen taxing the road to credibility without paving it.
0
3
4
New study from Denmark 🇩🇰 of over 1.5 MILLION people who received an mRNA Covid vaccine NO increased risk of 29 different adverse events Filter out the noise. Look at real data. mRNA vaccines are incredibly safe. https://t.co/G2WmY2RbaC
jamanetwork.com
This cohort study investigates the association between booster vaccinations containing the JN.1 lineage and 29 serious adverse events in Denmark.
945
4K
16K
Successfully identified spindle cells at tumor board and this must have been how Neo felt when he could see the Matrix
11
5
136
🚨 BREAKING | Press Release today DESTINY-Breast11 🧪 Neoadjuvant Enhertu ➕ THP showed ⭐ statistically significant & clinically meaningful improvement in pCR vs ddAC➕THP In high-risk ⚠️, locally advanced HER2+ 🧬 early breast cancer Early EFS trend 📈 also favored Enhertu!
4
15
80
👉 Two practice changing trials that will shape a new era in the treatment of patients with SCLC #ASCO25 #LCSM @SclcSMASHERS
2
49
132
👉🏽Out in @JCO_ASCO
#Taletrectinib Next Gen TKI in ROS1+ Non–Small Cell Lung Cancer: #TRUST pooled analysis 🎯TKI-naïve/pretreated: ORR 88.8/55.8%, 🧠Intracranial-ORR 76.5/65.6%, mPFS 45.6/9.7mo ➡️AEs: LFT abnormalities, diarrhea, edema, less neuro AEs @MP_3855 @n8pennell
1
18
51
An excellent debate here in #ELCC25 on the optimal choice for 1st Line treatment of EGFR pos #NSCLC : ⭐️. Osimertinib monotherapy VS Combinations (FLAURA2/MARIPOSA) Insightful lectures by @ZPiotrowskaMD and @APassaroMD focusing on efficacy endpoints, biology, toxicity and
3
57
153
Research from our Exercise Medicine Research Institute and led by one of our PhD students @FBettariga Francesco Bettariga was featured on the @Channel9 News in Perth, Western Australia and produced by @EdithCowanUni graduate - Brooke Comerford @brcomerford. Strong evidence that
1
4
20
He died #OnThisDay 6 years ago, & #F1 & the #FIA still miss him every single day. #RIPCharlieWhiting
91
149
2K
Guiding Treatment for Patients With Prostate Cancer With Biochemical Recurrence After Prostatectomy https://t.co/2TF9uZEFk7 with @AmarUKishan @DrSpratticus Thanks @ASCO Daily News Related @NatRevUrol article: https://t.co/AFzrHLoEYW
https://t.co/kfBMkjK6lD
Salvage therapy for prostate cancer after prostatectomy: international consensus on evaluation and management @NatRevUrol
https://t.co/LBrAPCuOaO
https://t.co/AFzrHLoEYW
#PCSM
3
94
207